Back to top

Analyst Blog

Biogen Idec (BIIB - Analyst Report) and partner Swedish Orphan Biovitrum AB (Sobi) reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG).

The study, which evaluated the safety, efficacy and pharmacokinetics of Eloctate, showed that twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in previously treated children (aged below 12 years) suffering from severe hemophilia A. Eloctate was found to be generally well-tolerated with no inhibitors being detected.

Eloctate is currently under the U.S. Food and Drug Administration (FDA) review for the treatment of hemophilia A in adults. A feedback from the FDA should be out by mid-2014.

Meanwhile, Biogen is conducting the phase III Kids B-LONG study with Alprolix for the treatment of hemophilia B in children below 12 years of age. Results from both these studies will help the company file for pediatric indications and also support marketing approval in the EU.

Alprolix is already approved in the U.S. and Canada for the treatment of hemophilia B in adults (> 17 years). Biogen plans to launch Alprolix in the U.S. in early May 2014.

We note that Biogen has another candidate, Plegridy, under review in the U.S. and the EU for the treatment of relapsing-remitting multiple sclerosis. A response should be out in the second half of 2014.

We expect 2014 to be a catalyst rich year for Biogen with several data-readouts expected this year.

Biogen carries a Zacks Rank #3 (Hold). Some better-ranked biotech stocks include Amgen Inc. (AMGN - Analyst Report), ZIOPHARM Oncology, Inc. (ZIOP - Snapshot Report) and Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report). While Amgen and ZIOPHARM carry a Zacks Rank #1 (Strong Buy), Alexion holds a Zacks Rank #2 (Buy).

Read the Full Research Report on ALXN
Read the Full Research Report on AMGN
Read the Full Research Report on ZIOP
Read the Full Research Report on BIIB


Zacks Investment Research

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%